
06-15.05

PTO/SB/21 (09-04)

Under the Paperwork Reduction Act of 1995, no	o persons are required	U.S. Patent and	Trader	tor use through 07/31/2006. OMB 0651-0031 mark Office; U.S. DEPARTMENT OF COMME mation unless it displays a valid OMB control nur
		Application Number		09/202,791
TRANSMITT	Filing Date		(Intl) June 26, 1997	
FORM	First Named Inventor		Kouji MATSUSHIMA	
	r initial filing)	Art Unit		1651
(to be used for all correspondence after initial filing)		Examiner Name		D. Ware
Total Number of Pages in This Submiss	Attorney Docket Nu	mber	350292000500	
EN	ICLOSURES	(Check all that a	pply)	
Fee Transmittal Form	Drawing(s)		ſ	After Allowance Communication to TC
Fee Attached	Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences
Amendment/Reply	Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final	Petition to C			Proprietary Information
Affidavits/declaration(s)	Power of Atto	rney, Revocation prrespondence Address		Status Letter
Extension of Time Request	Terminal Dis	·		Other Enclosure(s) (please Identify below):
Express Abandonment Request	Request for			Form PTO/SB/08a/b (1 page + duplicate)
x Information Disclosure Statement CD,		¬		2 References Return Receipt Postcard
Certified Copy of Priority Document(s)	Landscape Table on CD			
Reply to Missing Parts/ Incomplete Application	Remarks			
Reply to Missing Parts under 37 CFR 1.52 or 1.53	CUSTOMER	NO. 25225		
SIGNAT	UPE OF APPLIC	ANT, ATTORNEY, (OP A	CENT
Firm Name MORRISON & FOE		ANT, ATTORNET,		OLIVI
Signature				
Printed name Laurie L. Hill	7"			
June 14, 2005		Reg. N	0. [51,804
I hereby certify that this correspondence is to an envelope addressed to: MS AMENDME shown below. Dated: June 14, 2005 Signature		r Patents, P.O. Box 145		randria, VA 22313-1450, on the date



Patent Docket No. 350292000500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Kouji MATSUSHIMA et al.

Serial No.: 09/202,791

Filing Date: (Int'l) June 26, 1997

For: THERAPEUTIC AGENT FOR ACUTE

LUNG INJURY RESULTING FROM INDIRECT CAUSES COMPRISING ANTI-IL-8 ANTIBODY AS ACTIVE

INGREDIENT

Examiner: D. Ware

Group Art Unit: 1651

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the document listed on the attached Form PTO/SB/08a/b. Copies of documents numbers 1 and 3 are also submitted herewith. The document number 2 is currently unavailable to applicants, but a copy will be submitted at a later date. The Examiner is requested to make these documents of record.

The documents listed on the attached Form PTO/SB/08a/b was cited in an Office Action mailed on March 14, 2005, directed to a counterpart international or foreign application and has not been previously cited. A certification under 37 C.F.R. § 1.97(e)(1) follows:

sd-258684

I hereby certify that each item of information was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of this Information Disclosure Statement.

	This In	formation Disclosure Statement is submitted:					
	With	the application; accordingly, no fee or separate requirements are required.					
	Befor	Before the mailing of a first Office Action after the filing of a Request for Continued					
	Exam	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97					
	(e)(1)	has been provided.					
on	Withi	Within three months of the application filing date or before mailing of a first Office Action					
	on the	on the merits; accordingly, no fee or separate requirements are required. However, if					
	applic	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.					
\boxtimes	After	After receipt of a first Office Action on the merits but before mailing of a final Office Action					
	or No	tice of Allowance.					
		A fee is required. A check in the amount of is enclosed.					
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to					
		this submission in duplicate.					
\boxtimes	\boxtimes	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is					
	believed to be due.						
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the					
	issue	issue fee.					
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the					
		amount of is enclosed.					
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal					
		form (PTO/SB/17 is attached to this submission in duplicate.)					

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 350292000500.

Dated: June 14, 2005

Respectfully submitted,

Laurie L/Hill

Registration No.: 51,804

MORRISON & FOERSTER LLP

3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

(858) 720-7955

JUN 1 4 2005 S

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	09/202,791			
Filing Date	(Int'l) June 26, 1997			
First Named Inventor	Kouji MATSUSHIMA			
Art Unit	1651			
Examiner Name	D. Ware			
Attorney Docket Number	350292000500			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials* No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵	
	1.	WO-96/02576	02/1996			

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2.	Ganong, Review of Medical Physiology (18th Edition), Prentice Hall Int., Inc. (1997) pp.954-595 and 638-645	
	3.	Queen et al., Proc. Natl. Acad. Sci. USA (1989) 86:10029-10033	

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		_
Examiner	Date	
Signature	 Considered	
1 0 7 0 0 7 0		

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.